Neuland Laboratories reported mixed financial results for the quarter and nine months ended December 31, 2025, showing revenue growth but facing margin pressures due to product mix challenges and higher operating expenses. The company has scheduled an earnings call for February 9, 2026 at 17:30 IST to discuss these results.

Q3FY26 Financial Performance

The company's total income for Q3FY26 reached Rs. 447.8 crore, marking an 11.4% year-on-year increase from Rs. 401.9 crore in Q3FY25. However, profitability metrics showed a contrasting trend with EBITDA declining to Rs. 85.0 crore compared to Rs. 90.3 crore in the previous year.

Nine-Month Performance Highlights

For the nine-month period ending December 31, 2025, Neuland Laboratories demonstrated steady revenue growth with total income rising 8.9% to Rs. 1,264.5 crore from Rs. 1,160.9 crore in the corresponding period last year. EBITDA for 9MFY26 remained at Rs. 284.0 crore.

Management Commentary and Business Outlook

Sucheth Davuluri, Vice Chairman and CEO, noted that while revenues aligned with the company's annual outlook, the product mix within businesses and increased operating expenses impacted EBITDA margins. He emphasized continued business momentum driving long-term investments to capitalize on growth opportunities.

Saharsh Davuluri, Vice Chairman and Managing Director, highlighted increasing customer interest in the company's capabilities as a proven commercial NCE drug substance manufacturer and innovation partner. The investments are attracting both existing and new customers seeking specific niche capabilities.

Earnings Call Details

The company will conduct a one-hour earnings call at 17:30 IST on February 9, 2026, where management will discuss the company's performance and answer questions from participants. The transcript of the conference call will be uploaded on the company website in due course.

Operational Developments

The company reported several key operational metrics and developments including working capital days of sale improved to 145 days in Q3FY26 from 155 days in Q2FY26, primarily due to decreased receivables. The board approved R&D facility relocation to a leased 140,000 square feet facility at Genome Valley, with capital expenditure outflow of Rs. 254.0 crore during 9MFY26.

Neuland laboratories has announced that its Board of Directors will convene on February 9, 2026, to approve the company's unaudited financial results for the third quarter of fiscal year 2026. The pharmaceutical company made this announcement on January 21, 2026, in compliance with Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Details

The scheduled board meeting will focus on approving and taking on record the unaudited financial results for both standalone and consolidated operations. The results will cover the quarter and nine months ended December 31, 2025.

Trading Window Restrictions

In accordance with the company's Insider Trading Code, Neuland Laboratories has implemented trading window restrictions for its equity shares. The trading window closure, which began on January 1, 2026, will remain in effect until 48 hours after the declaration of the unaudited financial results to the stock exchanges.

This measure ensures compliance with insider trading regulations and maintains market integrity during the financial results announcement period. The company had previously communicated about these restrictions in a letter dated December 26, 2025.

Regulatory Compliance

The announcement demonstrates Neuland Laboratories' commitment to maintaining transparency and adhering to regulatory requirements. Company Secretary Sarada Bhamidipati signed the official communication, which was addressed to both BSE Limited and The National Stock Exchange of India Ltd.

The notification serves as formal intimation to stakeholders about the upcoming financial disclosure and ensures all regulatory protocols are followed in accordance with SEBI guidelines.